Artificial Intelligence (AI) group BenevolentAI has appointed Dr Nathan Brown as its new head of cheminformatics.
Brown joins the group from the Institute of Cancer Research (ICR), where he founded and led the new In Silico Medicinal Chemistry Group, which focussed on medicinal chemistry research towards novel cancer treatments.
He also has experience as a software designer and has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology.
Jackie Hunter, CEO of BenevolentBio, the bioscience subsidiary of BenevolentAI, said: “Nathan is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry.
“He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published. We are delighted to have him on board.”
Brown succeeds Mark Davies who has been promoted to vice president, Biomedical Informatics.